AU2012289964B2 - Trans-clomiphene metabolites and uses thereof - Google Patents

Trans-clomiphene metabolites and uses thereof Download PDF

Info

Publication number
AU2012289964B2
AU2012289964B2 AU2012289964A AU2012289964A AU2012289964B2 AU 2012289964 B2 AU2012289964 B2 AU 2012289964B2 AU 2012289964 A AU2012289964 A AU 2012289964A AU 2012289964 A AU2012289964 A AU 2012289964A AU 2012289964 B2 AU2012289964 B2 AU 2012289964B2
Authority
AU
Australia
Prior art keywords
clomiphene
trans
metabolite
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012289964A
Other languages
English (en)
Other versions
AU2012289964A1 (en
Inventor
Joseph S. Podolski
Ronald D. Wiehle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Repros Therapeutics Inc
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46724628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012289964(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of AU2012289964A1 publication Critical patent/AU2012289964A1/en
Application granted granted Critical
Publication of AU2012289964B2 publication Critical patent/AU2012289964B2/en
Priority to AU2017204171A priority Critical patent/AU2017204171A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2012289964A 2011-08-04 2012-08-03 Trans-clomiphene metabolites and uses thereof Ceased AU2012289964B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017204171A AU2017204171A1 (en) 2011-08-04 2017-06-20 Trans-Clomiphene Metabolites And Uses Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515278P 2011-08-04 2011-08-04
US61/515,278 2011-08-04
PCT/US2012/049451 WO2013020017A1 (en) 2011-08-04 2012-08-03 Trans-clomiphene metabolites and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017204171A Division AU2017204171A1 (en) 2011-08-04 2017-06-20 Trans-Clomiphene Metabolites And Uses Thereof

Publications (2)

Publication Number Publication Date
AU2012289964A1 AU2012289964A1 (en) 2014-01-30
AU2012289964B2 true AU2012289964B2 (en) 2017-03-23

Family

ID=46724628

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012289964A Ceased AU2012289964B2 (en) 2011-08-04 2012-08-03 Trans-clomiphene metabolites and uses thereof
AU2017204171A Abandoned AU2017204171A1 (en) 2011-08-04 2017-06-20 Trans-Clomiphene Metabolites And Uses Thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017204171A Abandoned AU2017204171A1 (en) 2011-08-04 2017-06-20 Trans-Clomiphene Metabolites And Uses Thereof

Country Status (21)

Country Link
US (1) US9981906B2 (enExample)
EP (2) EP3351527A1 (enExample)
JP (2) JP6433785B2 (enExample)
KR (1) KR20140054110A (enExample)
CN (1) CN103702975B (enExample)
AU (2) AU2012289964B2 (enExample)
BR (1) BR112014000908A2 (enExample)
CA (1) CA2841572C (enExample)
CL (1) CL2014000268A1 (enExample)
CO (1) CO6862154A2 (enExample)
CR (1) CR20140124A (enExample)
EA (1) EA201490416A1 (enExample)
IL (1) IL230287B (enExample)
MX (1) MX355316B (enExample)
MY (2) MY191802A (enExample)
NI (1) NI201400008A (enExample)
PH (1) PH12014500144A1 (enExample)
SG (1) SG10201606425WA (enExample)
UA (1) UA113291C2 (enExample)
WO (1) WO2013020017A1 (enExample)
ZA (1) ZA201400406B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120284764A1 (en) * 2011-05-05 2012-11-08 Keith Ball Method and system for requesting services by a media device
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
SG10201704858PA (en) 2012-05-31 2017-07-28 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
CN104994877A (zh) 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬
EP2914268B1 (en) 2012-11-02 2018-07-04 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US20190008804A1 (en) * 2016-01-12 2019-01-10 Repros Therapeutics Inc. Trans-Clomiphene and Progesterone Receptor Antagonist Combination Therapy for Treating Hormone-Dependent Conditions
EP3419611A4 (en) * 2016-02-25 2019-10-16 Aspen Park Pharmaceuticals Inc. ORAL PHARMACEUTICAL FORM OF CLOMIPHIC ISOMERS AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF SECONDARY HYPOGONADISM
CN108463453A (zh) 2016-04-22 2018-08-28 意大利合成制造有限公司 用于制备具有针状晶体习性的柠檬酸恩氯米芬的方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0206021B1 (de) 1985-06-08 1988-08-10 ASTA Pharma AG Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
KR100326962B1 (ko) * 1992-09-15 2002-12-02 메렐 파마슈티칼스 인크. 타목시펜-내성종양치료용비대사성클로미펜유사체
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JPH10501814A (ja) 1994-06-17 1998-02-17 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ 生物的作用物質用のイン・シツゲル形成デリバリービヒクルおよびその使用方法
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
AU6824996A (en) 1995-08-17 1997-03-12 Dyer, Alison Margaret Controlled release products
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
ES2565163T3 (es) 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
IL132120A0 (en) 1997-04-03 2001-03-19 Guilford Pharm Inc Biodegradable terephthalate polyester-poly (phosphate) polymers compositions articles and methods for making and using the same
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US20040186185A1 (en) 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
EP1100330A4 (en) 1998-07-30 2004-04-14 Stoller Ets TREATMENT OF PLANTS WITH SALICYLIC ACID AND ORGANIC AMINES
DE69935335T2 (de) 1998-08-07 2007-11-22 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazole als modulatoren des östrogenrezeptors
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CO5180583A1 (es) 1999-06-11 2002-07-30 Watson Pharmaceuticals Inc Administracion de esteroides androgenicos no orales a las mujeres
AU6132700A (en) 1999-09-30 2001-04-05 Chienna B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
AU2991301A (en) 2000-01-28 2001-08-07 Endorecherche Inc. Selective estrogen receptor modulators in combination with estrogens
WO2001091744A1 (en) 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US7067557B2 (en) 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
CN100448487C (zh) 2000-08-11 2009-01-07 惠氏公司 治疗雌激素受体阳性癌的方法
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
US6743448B2 (en) 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
CA2453337C (en) 2001-07-09 2012-08-28 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP1429779A2 (en) 2001-09-21 2004-06-23 Merck & Co., Inc. Androstanes as androgen receptor modulators
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
MX2007000050A (es) 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
CN101115709B (zh) * 2004-12-13 2011-04-13 小野药品工业株式会社 氨基羧酸衍生物及其医药用途
KR20070100811A (ko) 2005-02-04 2007-10-11 레프로스 쎄라피우틱스 아이엔씨. 남성불임의 치료를 위한 트랜스―클로미펜을 이용한 물질과치료방법
EP1853298A2 (en) 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
NZ560551A (en) 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
US7576053B2 (en) 2005-06-13 2009-08-18 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
CN101309702A (zh) * 2005-08-05 2008-11-19 雷普罗斯治疗公司 使用克罗米酚治疗女性不育症的方法及其组合物
US7613937B2 (en) 2005-10-31 2009-11-03 Hewlett-Packard Development Company, L.P. Method and apparatus for utilizing a microcontroller to provide an automatic order and timing power and reset sequencer
CA2642761A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
ES2427924T3 (es) 2006-06-30 2013-11-04 Merck Sharp & Dohme Corp. Biomarcador IGFBP2
ES2381175T3 (es) 2007-06-26 2012-05-23 Media Patents, S. L. Dispositivo para gestionar grupos multidifusión
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
ES2718912T3 (es) * 2007-10-16 2019-07-05 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de la diabetes en hombres hipogonadales
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TW201500041A (zh) 2008-11-07 2015-01-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
CA2881604C (en) 2011-08-09 2021-09-14 Kenneth W. Adams Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
ES2681023T3 (es) 2012-02-29 2018-09-11 Repros Therapeutics Inc. Terapia de combinación para tratar el déficit de andrógenos
AU2013306393A1 (en) 2012-08-21 2015-02-19 Repros Therapeutics Inc. Trans-clomiphene formulations and uses thereof
CN103351304B (zh) 2013-07-01 2015-12-09 暨明医药科技（苏州）有限公司 一种克罗米芬的合成方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAUMANN, R. J. ET. AL. Biochemical Pharmacology, 1998, 55, 841-851 *
BOIAN, G. ET. AL. Analytical & Bioanalytical Chemistry, 2011, 400, 3429-3441 *
RUENITZ, P. C. ET. AL. Cancer Research, 1987, 47, 4015-4019 *
RUENITZ, P. C. ET. AL. Journal of Medicinal Chemistry, 1989, 32, 192-197 *

Also Published As

Publication number Publication date
AU2017204171A1 (en) 2017-07-13
CA2841572A1 (en) 2013-02-07
MX2014000825A (es) 2014-02-27
CR20140124A (es) 2014-05-13
JP6433785B2 (ja) 2018-12-05
MY191802A (en) 2022-07-15
MY170718A (en) 2019-08-27
IL230287A0 (en) 2014-03-06
NZ621892A (en) 2016-03-31
AU2012289964A1 (en) 2014-01-30
UA113291C2 (xx) 2017-01-10
JP2014529584A (ja) 2014-11-13
MX355316B (es) 2018-04-16
ZA201400406B (en) 2014-11-26
CL2014000268A1 (es) 2014-11-14
CN103702975A (zh) 2014-04-02
US20140163114A1 (en) 2014-06-12
PH12014500144A1 (en) 2014-02-24
KR20140054110A (ko) 2014-05-08
NI201400008A (es) 2015-12-10
WO2013020017A1 (en) 2013-02-07
BR112014000908A2 (pt) 2017-02-21
CO6862154A2 (es) 2014-02-10
HK1196349A1 (zh) 2014-12-12
EA201490416A1 (ru) 2014-11-28
SG10201606425WA (en) 2016-09-29
EP2744777A1 (en) 2014-06-25
IL230287B (en) 2019-07-31
CA2841572C (en) 2020-10-13
US9981906B2 (en) 2018-05-29
CN103702975B (zh) 2016-03-16
EP3351527A1 (en) 2018-07-25
JP2019023210A (ja) 2019-02-14

Similar Documents

Publication Publication Date Title
AU2012289964B2 (en) Trans-clomiphene metabolites and uses thereof
Y. Maximov et al. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice
TW200410711A (en) Prevention and treatment of androgen-deprivation induced osteoporosis
JP2021046448A (ja) 癌療法における使用のためのトランス−クロミフェン
US20210379040A1 (en) Combination treatment of liver disorders
TWI458478B (zh) 用於代謝症候群與第２型糖尿病的反式氯米芬
TW201922238A (zh) 包含lsz102及瑞博西利(ribociclib)之醫藥組合
CN1988909A (zh) 包含5－α还原酶抑制剂和SERM的组合物及其使用方法
NZ621892B2 (en) Trans-clomiphene metabolites and uses thereof
HK1196349B (zh) 反式-氯米芬代謝物及其用途
EP3300725A2 (en) Selective estrogen receptor modulators with short half-lives and uses thereof
JP2008511615A (ja) アンドロゲン欠乏症の治療法または予防法に使用する医薬調製物の製造に用いるエストロゲン受容体選択的調節物質
KR20230060465A (ko) 장내 glp-1 분비 촉진 및 염증 완화 효능을 가지는 아젤라산 조성물
HK1240110A1 (en) Selective estrogen receptor modulators with short half-lives and uses thereof
KR20180112048A (ko) 클로미펜 이성질체들의 경구 제형 및 이차 생식선 기능저하증 치료를 위하여 이들을 사용하는 방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired